β‐Blocker Use and Mortality in COPD Patients After Myocardial Infarction: A Swedish Nationwide Observational Study
Key result
Discharge with β-blockers in patients with COPD after myocardial infarction was associated with lower all-cause mortality compared to no β-blockers (HR 0.87; 95% CI 0.78 to 0.98).
Why the study?
Does β-blocker prescription at discharge reduce all-cause mortality in patients with COPD after myocardial infarction?
Population
4,858 patients with myocardial infarction and concomitant chronic obstructive pulmonary disease who were…
Comparison
β-blocker prescription at discharge vs Not discharged with β-blockers
Design
Cohort
Follow-up
maximum 7.2 years
Authors
Discussion
Loading...
Member takes
Implication
β-Blocker use post-MI in COPD was associated with lower mortality; leaves open causal benefit versus confounding, warranting RCTs.
Study Design
Type
Observational (n=4,858)
Multicenter
Yes
Structured PICO
Does β-blocker prescription at discharge reduce all-cause mortality in patients with COPD after myocardial infarction?
P
Population
4,858 patients with COPD discharged after a myocardial infarction, followed for up to 7.2 years.
E
Exposure
β-blocker prescription at discharge
C
Comparator
Not discharged with β-blockers
O
Outcome
All-cause mortalityhard clinical
Main Result
Hazard Ratio: 0.87 (95% CI 0.78–0.98)
β-blocker prescription at discharge is associated with reduced all-cause mortality in patients with COPD after myocardial infarction, suggesting this high-risk group benefits from standard secondary prevention.
Cite This Study
Andell et al. (2015) conducted an observational in Myocardial infarction with concomitant chronic obstructive pulmonary disease (COPD) (n=4,858). β-blockers vs. No β-blockers at discharge was evaluated on All-cause mortality (HR 0.87, 95% CI 0.78 to 0.98). Discharge with β-blockers in patients with COPD after myocardial infarction was associated with lower all-cause mortality compared to no β-blockers (HR 0.87; 95% CI 0.78 to 0.98).